Differentiation syndrome in acute promyelocytic leukaemia

Br J Haematol. 2019 Oct;187(2):157-162. doi: 10.1111/bjh.16151. Epub 2019 Aug 13.

Abstract

Acute promyelocytic leukaemia differentiation syndrome (APL DS) is seen when patients with APL are treated with all-trans retinoic acid (ATRA) and/or arsenic trioxide (ATO). Presenting symptoms are varied but frequently include dyspnoea, unexplained fever, weight gain >5 kg, unexplained hypotension, acute renal failure and a chest radiograph demonstrating pulmonary infiltrates or pleural or pericardial effusion. Immediate treatment with steroids at the first clinical suspicion is recommended and ATRA/ATO should be stopped in severe cases or if there is no response to treatment. The utility of steroid prophylaxis in order to prevent APL DS is less certain. Here we provide a detailed review of the pathogenesis, clinical signs and symptoms as well as management and prophylaxis strategies of APL DS.

Keywords: acute promyelocytic leukaemia; all-trans retinoic acid; arsenic trioxide; differentiation syndrome; retinoid acid syndrome.

Publication types

  • Review

MeSH terms

  • Acute Kidney Injury / chemically induced
  • Acute Kidney Injury / diagnostic imaging
  • Acute Kidney Injury / drug therapy
  • Arsenic Trioxide / adverse effects*
  • Arsenic Trioxide / therapeutic use
  • Cell Differentiation*
  • Humans
  • Hypotension / chemically induced
  • Hypotension / diagnostic imaging
  • Hypotension / drug therapy
  • Leukemia, Promyelocytic, Acute / diagnostic imaging*
  • Leukemia, Promyelocytic, Acute / drug therapy*
  • Leukemia, Promyelocytic, Acute / metabolism
  • Pulmonary Edema / chemically induced
  • Pulmonary Edema / diagnostic imaging
  • Pulmonary Edema / drug therapy
  • Steroids / therapeutic use*
  • Syndrome
  • Tretinoin / adverse effects*
  • Tretinoin / therapeutic use

Substances

  • Steroids
  • Tretinoin
  • Arsenic Trioxide